(Reuters) - Actelion Ltd, which is fighting a boardroom battle with activist hedge fund Elliott Advisors, used its first-quarter results and backing from a big shareholder and investor group to argue its strategy was sound. The company noted large shareholder BB Biotech had come out in its support ahead of an annual general meeting (AGM) set for May 5 and said it also had the backing of Germany-based independent proxy voting service IVOX.
